- Home
- PHAR vs NMCO Comparison
PHAR vs NMCO Comparison
Compare PHAR & NMCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHAR
- NMCO
- Stock Information
- Founded
- PHAR 1988
- NMCO 2019
- Country
- PHAR Netherlands
- NMCO United States
- Employees
- PHAR N/A
- NMCO N/A
- Industry
- PHAR Biotechnology: Pharmaceutical Preparations
- NMCO Finance/Investors Services
- Sector
- PHAR Health Care
- NMCO Finance
- Exchange
- PHAR Nasdaq
- NMCO Nasdaq
- Market Cap
- PHAR 731.1M
- NMCO 577.1M
- IPO Year
- PHAR N/A
- NMCO N/A
- Fundamental
- Price
- PHAR $10.00
- NMCO $10.49
- Analyst Decision
- PHAR Strong Buy
- NMCO
- Analyst Count
- PHAR 3
- NMCO 0
- Target Price
- PHAR $30.00
- NMCO N/A
- AVG Volume (30 Days)
- PHAR 3.6K
- NMCO 207.6K
- Earning Date
- PHAR 07-31-2025
- NMCO 01-01-0001
- Dividend Yield
- PHAR N/A
- NMCO 5.43%
- EPS Growth
- PHAR N/A
- NMCO N/A
- EPS
- PHAR N/A
- NMCO N/A
- Revenue
- PHAR $320,708,000.00
- NMCO N/A
- Revenue This Year
- PHAR $13.31
- NMCO N/A
- Revenue Next Year
- PHAR $7.68
- NMCO N/A
- P/E Ratio
- PHAR N/A
- NMCO N/A
- Revenue Growth
- PHAR 24.13
- NMCO N/A
- 52 Week Low
- PHAR $6.65
- NMCO $8.52
- 52 Week High
- PHAR $12.61
- NMCO $11.64
- Technical
- Relative Strength Index (RSI)
- PHAR 43.61
- NMCO 44.18
- Support Level
- PHAR $9.99
- NMCO $10.76
- Resistance Level
- PHAR $10.59
- NMCO $10.66
- Average True Range (ATR)
- PHAR 0.35
- NMCO 0.11
- MACD
- PHAR -0.14
- NMCO -0.02
- Stochastic Oscillator
- PHAR 7.45
- NMCO 25.00
About PHAR Pharming Group N.V.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.
About NMCO Nuveen Municipal Credit Opportunities Fund
Nuveen Municipal Credit Opps Fund is a closed-end fund. The fund's objective is to provide a high level of current income exempt from regular U.S. federal income tax and secondarily, total return. It invests in high yielding, low-to medium-quality municipal securities and uses leverage.